COO
Michael Halpin is the Chief Operating Officer (COO) of Vericel Corp (NASDAQ: VCEL), a biotechnology company focused on advanced therapies for sports medicine and severe burn care.[[2]](https://www.vcel.com/about/)[[1]](https://www.investing.com/news/insider-trading-news/vericels-coo-michael-halpin-sells-495200-in-stock-93CH-3910114) He joined Vericel in April 2017, bringing over 28 years of experience in regulatory affairs, quality assurance, and clinical research across medical devices, biologics, and advanced therapies.[[2]](https://www.vcel.com/about/)[[4]](https://boston.devicetalks.com/speaker/michael-halpin/) Prior to Vericel, Halpin served at Sanofi and Genzyme Corporation, most recently as Vice President and North American Region Regulatory Head for Sanofi Genzyme’s rare disease, immuno-inflammatory, and multiple sclerosis products, and earlier as VP of Regulatory Affairs for Genzyme’s biosurgery division overseeing products like Carticel®, Epicel®, and MACI®.[[2]](https://www.vcel.com/about/)[[4]](https://boston.devicetalks.com/speaker/michael-halpin/) His earlier career includes regulatory, quality, and clinical roles at Abbott/MediSense, C.R. Bard, and Abiomed.[[2]](https://www.vcel.com/about/)[[4]](https://boston.devicetalks.com/speaker/michael-halpin/)
Halpin holds a master’s degree in biomedical engineering and a bachelor’s degree in biochemistry from the University of Virginia.[[2]](https://www.vcel.com/about/) As COO, he has been involved in recent insider transactions, including selling 10,000 shares at $49.52 in late 2024 under a Rule 10b5-1 plan, exercising options for 10,000 shares at $16.66, and further sales in 2025 and January 2026, while retaining 15,539 shares directly.[[1]](https://www.investing.com/news/insider-trading-news/vericels-coo-michael-halpin-sells-495200-in-stock-93CH-3910114)[[3]](https://www.ainvest.com/news/vericel-corp-coo-halpin-michael-buys-sells-shares-january-7-2026-2601/)[[6]](https://www.tradingview.com/news/tradingview:df2e4322a5dc5:0-vericel-corp-coo-michael-halpin-sells-shares/) At 63 years old, Halpin continues to contribute to Vericel’s operations amid the company’s strong 2024 financial performance and growth outlook.[[7]](https://www.patria.cz/akcie/7e240a04-0ec3-46c9-a690-b9cd68f6317d/vericel/ospolecnosti.html)[[1]](https://www.investing.com/news/insider-trading-news/vericels-coo-michael-halpin-sells-495200-in-stock-93CH-3910114)
View full insider profile →
